SCHEMBL25877653

SCHEMBL25877653

O=C(Nc1ccc(F)c([N+](=O)[O-])c1)C1CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.60
KMT2A Q03164 7/20 0.60
MEN1 O00255 6/20 0.60
MAPT P10636 5/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
HTT P42858 2/20 0.60
NAMPT P43490 1/20 0.60
ALDH1A1 P00352 5/20 0.56
POLB P06746 2/20 0.56
GAA P10253 2/20 0.56
RECQL P46063 1/20 0.53
RAB9A P51151 2/20 0.53
MAPK1 P28482 1/20 0.53
NPC1 O15118 1/20 0.51
TRPV1 Q8NER1 1/20 0.51
CA1 P00915 1/20 0.50
MMP2 P08253 1/20 0.50
CA14 Q9ULX7 1/20 0.50
MCL1 Q07820 1/20 0.50
HCRTR1 O43613 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28799461 0.94 LMNA (0.58) LMNAKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL8031444 0.93 MEN1 (0.56) LMNAKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL1504563 0.83 RAB9A (0.72) LMNAKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL7823892 0.82 L3MBTL1 (0.64) LMNAKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL11729459 0.82 NAMPT (0.58) LMNAKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL2853073 0.80 LMNA (0.73) LMNAKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL2853072 0.80 LMNA (0.73) LMNAKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL584346 0.79 ALDH1A1 (0.73) LMNAKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL20560143 0.79 LMNA (0.67) LMNAKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL5523784 0.79 MEN1 (0.67) LMNAKMT2AMEN1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed
WO-2021263079-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. (US) 2021-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B LMNA 387/4885KMT2A 3032/4885MEN1 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.